JNJ: 2Q26 Quick Take: Q2 Sales/EPS Beat but MedTech Underperformed; 2026 Sales/EPS Guidance Raised

Research evidence excerpt

JNJ: 2Q26 Quick Take: Q2 Sales/EPS Beat but MedTech Underperformed; 2026 Sales/EPS Guidance Raised

go Securities, LLC is regulated under the laws of the United

States and Wells Fargo Securities International Limited is regulated under laws of the United Kingdom. All such laws differ from Australian laws. Any offer or

documentation provided to Australian recipients by Wells Fargo Securities, LLC or Wells Fargo Securities International Limited in the course of providing the

financial services will be prepared in accordance with the laws of the United States or United Kingdom and not Australian laws.

Canada – This report is distributed in Canada by Wells Fargo Securities Canada, Ltd., a registered investment dealer in Canada and member of the Canadian

Investment Regulatory Organization (CIRO) and, Member – Canadian Investor Protection Fund (CIPF). Wells Fargo Securities, LLC’s research analysts may

participate in company events such as site visits but are generally prohibited from accepting payment or reimbursement by the subject companies for associated

expenses unless pre-authorized by members of Research Management.

China – Strictly Private and Confidential. For the sole use of the recipient only. Not to be copied or redistributed within the People’s Republic of China.

Brazil - This report was not created for distribution to investors resident in Brazil or to the Brazilian public in general. Wells Fargo Securities, LLC is a broker-dealer

registered in United States of America with and regulated by the U.S. Securities and Exchange Commission. Wells Fargo Securities, LLC is not registered in Brazil

and its products, including this report and the securities mentioned in this report, have not been and will not be publicly issued, placed, distributed, offered or